- For Regulatory Affairs: the program shows how one molecule can create three distinct evidence paths.
- For Clinical Research: the immediate issue is whether different dose levels produce the intended benefit-risk balance in each population.
- for Quality and development governance teams: the case reinforces the need to keep dose, safety, endpoint, and study decisions traceable as one asset expands.
Why Tyra’s Dabogratinib Phase 2 Readout Could Define Its Three-Indication Strategy
Tyra, founded in 2018 by Todd Harris and Daniel Bensen, calls the approach its “dabogratinib 3×3” strategy. Dabogratinib, formerly TYRA-300, is in Phase 2 development for low-grade upper tract urothelial carcinoma, intermediate-risk non-muscle invasive bladder cancer, and achondroplasia. Although these diseases differ clinically, each is linked to abnormal FGFR3 activity.
However, a shared molecular target does not mean a shared dose or clinical evidence package.
The table below compares Tyra’s three Phase 2 programs, highlighting how dose strategy, indication, and upcoming clinical milestones differ despite the shared FGFR3 target.
| Program | Indication | Dose Strategy | Next Milestone |
|---|---|---|---|
|
SURF302 |
IR NMIBC |
50 mg and 60 mg once daily |
Initial data, September 2026 |
|
SURF303 |
LG-UTUC |
60 mg and 80 mg once daily |
Initial data, 2027 |
|
BEACH301 |
Achondroplasia |
Dose escalation through 0.625 mg/kg |
Initial data, end of Q1 2027 |
Tyra expects the SURF302 readout to include safety results from more than 40 patients and efficacy data from more than 20 patients across the two dose cohorts. Meanwhile, SURF303 is a Phase 2a/b study designed with pivotal intent.
BEACH301 presents a different dose-setting challenge. The study evaluates dabogratinib in children aged 3 to 10 with achondroplasia. After four dose levels were cleared with no notable safety events reported by Tyra, the Data Safety Monitoring Committee authorized a fifth level at 0.625 mg/kg. Initial safety and six-month annualized height velocity data from approximately 25 children are expected by the end of Q1 2027.
One FGFR3 Target, Three Indications: Why the Evidence Burden Changes
Tyra’s three dabogratinib programs share the same FGFR3 target but address very different clinical needs. While the oncology programs aim to reduce treatment burden and preserve organs, achondroplasia requires a distinct dose and benefit-risk strategy. As a result, each indication needs its own dose justification, safety assessment, endpoints, and clinical evidence. Development teams should keep these decisions indication-specific and align Clinical Development with Regulatory Affairs before major data readouts.
What Pharma Teams Should Watch as Tyra’s First Phase 2 Data Nears
The closest milestone is SURF302 in September 2026. After that, attention shifts to BEACH301 at the end of Q1 2027 and SURF303 during 2027. Those results will begin to show whether Tyra’s shared FGFR3 thesis can support three distinct clinical development paths.
How Zamann Pharma Supports Risk-Based Quality and Development Decisions
For organizations managing development decisions that later feed into regulated quality operations, Zamann Pharma’s Quality Management System service is the strongest natural match, particularly around risk management, change control, and controlled quality processes. Explore the service if your team needs practical support strengthening governance around complex pharmaceutical programs.
Source: Pharmavoice.Com